CCL2 and glioblastoma: Although targeting CCL2-mediated recruitment of MDMs has not yet been clinically explored, combining CCL2 inhibition with anti-PD-1 treatment prolonged survival in GSC glioblastoma-bearing mice, and may be a potential candidate for future studies (99).